This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodins, K. Articles by Fox, S. B. Search for Related Content PubMed PubMed Citation Articles by Rodins, K. Articles by Fox, S. B.

Minichromosome Maintenance Protein 2 Expression in Normal Kidney and Renal Cell Carcinomas

Relationship to Tumor Dormancy and Potential Clinical Utility¹

Anatomical Pathology, Canterbury Health Laboratories, Christchurch Hospital, Christchurch, New Zealand 8001 [K. R., M. C., S. B. F.], and Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge CB2 2XZ, United Kingdom [N. C.]

Purpose: A major problem in the management of patients with renal cell carcinoma is predicting tumor behavior. In the search for more accurate markers of prognosis, tumor cell proliferation has been investigated. These studies have mostly used antibodies directed against Ki-67 or proliferating cell nuclear antigen and have given conflicting results, findings that are likely because of a combination of specificity and methodological differences. Minichromosome maintenance (Mcm) proteins are a series of closely related proteins that are components of the prereplicative complex. The Mcm proteins are essential for initiating eukaryotic DNA replication and serve as useful markers of proliferating cells.

Experimental Design: The aims of this study were to determine the frequency and pattern of Mcm2 expression by immunohistochemistry in normal kidney (n = 10) and renal tumors [n = 56; clear cell n = 36; chromophil (papillary) n = 7; oncocytoma n = 5; and transitional cell carcinoma n = 8], compare its sensitivity to the established proliferation marker Ki-67, examine for differences in tumors derived from stable and labile epithelial cell populations in the kidney, and assess the relationship of Mcm2 proliferation to clinicopathological characteristics of kidney tumors. In addition, to additionally investigate the issue of tumor dormancy we wished to assess the relationship between Mcm2 labeling index (LI) and the angiogenic factors angiopoietin-1 (Ang) and Ang-2.

Results: In normal tissues, Mcm2 nuclear labeling was identified in both glomeruli (LI median 0.35%; range 0–1.7) and renal tubules (LI median 0.3%; range 0.1–2.9%). In tumors Mcm2 labeling was predominantly at the periphery with LIs ranging from 0.2–91.5%, which was significantly greater than Ki-67 LI (0.2–40.5%; P < 0.001). Mcm2 LI was also significantly higher in tumors derived from a labile epithelium (transitional cell carcinomas) than a stable epithelium (renal cell carcinomas; P = 0.013). A significant association was also demonstrated between Mcm2 LI and tumor grade (P = 0.0006), and angiogenic phenotype (defined by Ang expression; P = 0.03) but not with patient age (P = 0.84), patient sex (P = 0.25), tumor size (P = 0.74), or stage (P = 0.33). Furthermore, although not significant, a survival analysis demonstrated that 100% of patients with a low Mcm2 LI survived compared with 84% of those with a high Mcm2 LI over the follow-up period (up to 53.2 months; P = 0.14).

Conclusions: This is the first study examining Mcm2 protein in normal and tumor kidney samples, and the first to perform histological subgroup analysis. It shows that Mcm2 is a superior marker to Ki-67 in the assessment of cell cycle entry in histological archival material and that normal kidney has a subset of cells within the glomerular and tubular compartments that are in cycle. It demonstrates that the frequency of cells in cycle in tumors formed from stable or labile epithelial populations mirrors that in the nonneoplastic epithelium. This study additionally demonstrates that the number of cells in cycle in tumors is limited by the angiogenic phenotype and supports animal models that show angiogenesis determines the likelihood of tumor dormancy. Additional study to confirm the clinical utility of Mcm2 as a prognostic marker is now indicated.

This article has been cited by other articles:

				A Hanna-Morris, S Badvie, P Cohen, T McCullough, H J N Andreyev, and T G Allen-Mersh Minichromosome maintenance protein 2 (MCM2) is a stronger discriminator of increased proliferation in mucosa adjacent to colorectal cancer than Ki-67 J. Clin. Pathol., April 1, 2009; 62(4): 325 - 330. [Abstract] [Full Text] [PDF]

				M. NOWAK, J. A. MADEJ, and P. DZIEGIEL Correlation Between MCM-3 Protein Expression and Grade of Malignancy in Mammary Adenocarcinomas and Soft Tissue Fibrosarcomas in Dogs In Vivo, January 1, 2009; 23(1): 49 - 53. [Abstract] [Full Text] [PDF]

				G. Elberg, D. Elberg, T. V. Lewis, S. Guruswamy, L. Chen, C. J. Logan, M. D. Chan, and M. A. Turman EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1622 - F1632. [Abstract] [Full Text] [PDF]

				A Mohan, M Kandalam, H L Ramkumar, L Gopal, and S Krishnakumar Stem cell markers: ABCG2 and MCM2 expression in retinoblastoma Br. J. Ophthalmol., July 1, 2006; 90(7): 889 - 893. [Abstract] [Full Text] [PDF]

				S. L. Forsburg Eukaryotic MCM Proteins: Beyond Replication Initiation Microbiol. Mol. Biol. Rev., March 1, 2004; 68(1): 109 - 131. [Abstract] [Full Text] [PDF]

				Y. Tani, R. R. Maronpot, J. F. Foley, J. K. Haseman, N. J. Walker, and A. Nyska Follicular Epithelial Cell Hypertrophy Induced by Chronic Oral Administration of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Female Harlan Sprague--Dawley Rats Toxicol Pathol, January 1, 2004; 32(1): 41 - 49. [Abstract] [PDF]

				M. A. Gonzalez, S. E. Pinder, G. Callagy, S. L. Vowler, L. S. Morris, K. Bird, J. A. Bell, R. A. Laskey, and N. Coleman Minichromosome Maintenance Protein 2 Is a Strong Independent Prognostic Marker in Breast Cancer J. Clin. Oncol., December 1, 2003; 21(23): 4306 - 4313. [Abstract] [Full Text] [PDF]

				K. Middleton, W. Peh, S. Southern, H. Griffin, K. Sotlar, T. Nakahara, A. El-Sherif, L. Morris, R. Seth, M. Hibma, et al. Organization of Human Papillomavirus Productive Cycle during Neoplastic Progression Provides a Basis for Selection of Diagnostic Markers J. Virol., October 1, 2003; 77(19): 10186 - 10201. [Abstract] [Full Text] [PDF]

				P. S. Sirieix, M. O'Donovan, J. Brown, V. Save, N. Coleman, and R. C. Fitzgerald Surface Expression of Minichromosome Maintenance Proteins Provides a Novel Method for Detecting Patients at Risk for Developing Adenocarcinoma in Barrett's Esophagus Clin. Cancer Res., July 1, 2003; 9(7): 2560 - 2566. [Abstract] [Full Text] [PDF]